Embecta (NASDAQ:EMBC) Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices. These products are designed to support patients across the spectrum of diabetes management, from intensive insulin therapy to routine self-testing and continuous glucose monitoring systems.
Embecta serves customers in more than 100 countries through a network of direct and indirect distribution channels that include hospitals, clinics, retail pharmacies and e-commerce platforms. The company maintains a global footprint with manufacturing and distribution sites strategically located across North America, Europe and the Asia-Pacific region to ensure supply continuity and responsiveness to regional regulatory requirements.
Embecta is led by President and Chief Executive Officer Anthony J. Parker, whose leadership team leverages deep expertise in medical technology to drive innovation and expand the company’s product pipeline. Going forward, Embecta aims to enhance patient outcomes by advancing next-generation insulin delivery systems and digital health integrations that support personalized diabetes management.
